LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) trial: preliminary observations.
Not exact matches
This press release contains forward - looking statements, including expectations regarding adjudication of MACE events,
results and related timing and announcements with respect to Amarin's REDUCE - IT
cardiovascular outcomes study; expectations related to the final
outcomes of the REDUCE - IT study and the anticipated successful completion of the REDUCE - IT study; and statements regarding the potential and therapeutic benefits of Vascepa.
The second reason is that Amarin will finally announce the top - line
results of its large
cardiovascular outcomes trial for Vascepa sometime in the third quarter of 2018.
«While these observational data can not prove that treating patients based on the
results of CTA testing will automatically
result in better health
outcomes, they do provide new information enabling a more informed choice of testing for patients with stable chest pain, especially for predicting future
cardiovascular risk.»
Those
results, reported in a 2015 New England Journal paper, found similar
outcomes for both strategies in terms of the incidence of future
cardiovascular events.
«Although this study demonstrates that atrasentan treatment
results in clinically significant albuminuria reduction with minimal fluid overload - related or
cardiovascular side effects, a larger study on hard renal and / or cardiac
outcomes is needed to further support these findings,» said Dr. de Zeeuw.
However, far from encouraging people to consume unhealthy fats, this promising
outcome may
result in new therapeutic uses of Incas» peanut for the treatment of both hypertriglyceridemia and type 2 diabetes, as well as in new ways of preventing
cardiovascular and metabolic diseases.